GF
UTHR icon

Gabelli Funds’s United Therapeutics UTHR Stock Holding History

Gabelli Funds’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,000
Closed -$284K – 1081
2020
Q1 		$284K Sell
3,000
-2,000
-40% -$190K ﹤0.01% 943
2019
Q4 		$440K Hold
5,000
– – ﹤0.01% 956
2019
Q3 		$399K Hold
5,000
– – ﹤0.01% 985
2019
Q2 		$390K Buy
+5,000
New +$468K ﹤0.01% 1012
2019
Q1 		– Sell
-3,700
Closed -$403K – 1167
2018
Q4 		$403K Hold
3,700
– – ﹤0.01% 1002
2018
Q3 		$473K Hold
3,700
– – ﹤0.01% 1019
2018
Q2 		$419K Buy
3,700
+1,000
+37% +$110K ﹤0.01% 1029
2018
Q1 		$303K Buy
+2,700
New +$343K ﹤0.01% 1063

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Gabelli Funds's UTHR Position: Q2 2020 in Review

Gabelli Funds sold out of United Therapeutics (UTHR) in Q2 2020, closing a stake of 3,000 shares — an estimated $284K sold.

Gabelli Funds first reported a position in UTHR in Q1 2018 and held it in 8 quarters. The position peaked at $473K in Q3 2018. 349 funds tracked by Wall St. Rank hold UTHR as of Q2 2020.

  • Gabelli Funds reported no remaining United Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Gabelli Funds sold 3,000 United Therapeutics shares in Q2 2020, an estimated $284K.
  • Gabelli Funds first reported a position in United Therapeutics in Q1 2018 and held it in 8 quarters.
  • Gabelli Funds's United Therapeutics position peaked at $473K in Q3 2018.
  • 349 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2020.

Based on Gabelli Funds's 13F filing for Q2 2020, filed 13 Aug 2020.